Fewer Bleeds, Smarter Steroids: Apixaban vs Rivaroxaban and CRP-Guided Steroids for Pneumonia

With Special Guest Dr. Adam Jaffe

In this episode of Inpatient Update, Dr. Mason Turner is joined by hospitalist Dr. Adam Jaffe to tackle two high-impact clinical questions:

• Is there a clear winner among DOACs? 
• Who actually benefits from steroids in community-acquired pneumonia? 

Two common decisions. New data. Practice-changing implications. 

Articles & PubMed Links

Apixaban vs Rivaroxaban for VTE (Head-to-Head RCT)

New England Journal of Medicine (2026)

Randomized trial (n=2,760) comparing:

• Apixaban
  vs 
• Rivaroxaban 

Population:

• Acute VTE 
• Excluded: active cancer, extreme obesity, other anticoagulation indications 

Key Findings

• ↓ Clinically significant bleeding with apixaban 
  • ~54% relative risk reduction 
  • NNT ≈ 27 
• ↓ Major bleeding (0.4% vs 2.4%) 
• No difference in: 
  • Recurrent VTE 
  • Mortality 

Interpretation

• Same efficacy 
• Less bleeding with apixaban 

Takeaway

→ For new starts: Apixaban is the preferred DOAC

pubmed: https://pubmed.ncbi.nlm.nih.gov/41812192/

Corticosteroids in Community-Acquired Pneumonia (IPD Meta-analysis)

Lancet

Large meta-analysis (n=3,224 across 8 RCTs)

Compared:

• Steroids
  vs 
• Placebo 

Primary Outcome: 30-day mortality

• Absolute risk reduction: 2.2% 
• NNT = 46 

🔑 The Key Insight: CRP Matters

When stratified by inflammation:

CRP >200

• Mortality: 13% → 6% 
• Absolute risk reduction ≈ 7% 
• NNT ≈ 14 

CRP <200

• No mortality benefit 

Other Findings

• ↑ Hyperglycemia (expected) 
• ↑ Readmissions (7% vs 3.7%) 
• No clear signal that severity scores (PSI) identify benefit 

Interpretation

• Steroids are not for everyone 
• Benefit appears driven by high inflammatory states 

Takeaway

→ Consider steroids in CAP only if CRP is markedly elevated (~>200)
→ Routine use in all pneumonia is not supported

pubmed: https://pubmed.ncbi.nlm.nih.gov/39892408/

Practice-Changing Takeaways

• DOACs: 
  • Apixaban > rivaroxaban for bleeding 
  • Same clot prevention → choose apixaban for new starts 
• Pneumonia: 
  • Steroids may reduce mortality — but only in the right patient 
  • CRP can help identify who benefits 

Clinical Pearls

• The difference between DOACs is no longer “vibes” — we now have head-to-head data 
• Most steroid benefit in pneumonia appears inflammatory-driven, not severity-driven 
• CRP — often ignored — may actually guide meaningful decisions here 

Bottom Line

If you change nothing else this week:

• Start apixaban for new VTE patients 
• In pneumonia, check a CRP — and consider steroids if >200 

Fewer bleeds. Smarter steroids. Better outcomes.

Support the show

Want the cited articles and key takeaways? Join the email list:
https://subscribe.inpatientupdate.com/